spironolactone has been researched along with Ventricular Dysfunction, Left in 151 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1month in 476 patients." | 9.24 | Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac ( Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2017) |
| "In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity." | 9.24 | Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017) |
| " The investigation involved 6632 patients of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study." | 9.19 | Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s ( Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F, 2014) |
| "EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI) complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n = 3313)." | 9.19 | Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial. ( Adlam, D; Fay, R; Gunn, J; Iqbal, J; Parviz, Y; Pitt, B; Squire, I; Zannad, F, 2014) |
| "We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.16 | Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. ( Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F, 2012) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes." | 9.14 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. ( Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F, 2009) |
| "In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction." | 9.14 | Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP ( Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2009) |
| "Use of selective aldosterone blockade with eplerenone within the dose range of 25 to 50 mg/d in post-acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction who are treated with standard therapy improves outcomes without an excess of risk of hyperkalemia (> or =6." | 9.13 | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "In asymptomatic patients with moderate-severe aortic stenosis, eplerenone did not slow onset of LV systolic or diastolic dysfunction, decrease LV mass, or reduce progression of valve stenosis." | 9.13 | A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. ( Cowan, BR; Doughty, RN; Edwards, C; Freidlander, D; Kerr, AJ; Occleshaw, C; Richards, AM; Stewart, RA; Whalley, GA; White, HD; Williams, M; Young, AA; Zeng, I, 2008) |
| "The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI)." | 9.12 | Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. ( Burnier, M; Erne, P; Holm, MV; Schwenkglenks, M; Szucs, TD; Weintraub, WS; Zhang, Z, 2006) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), eplerenone reduced all-cause mortality by 15% (p = 0." | 9.11 | Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. ( Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F, 2005) |
| "Eplerenone compared with placebo in the treatment of heart failure after acute myocardial infarction is effective in reducing mortality and is cost-effective in increasing years of life by commonly used criteria." | 9.11 | Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| " We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure." | 9.10 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. ( Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F, 2003) |
| "Patients hospitalized for a first episode of acute myocardial infarction were blindly and randomly assigned to receive ramipril (2." | 9.08 | [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study]. ( Castro, P; Chávez, A; Chávez, E; Corbalán, R; Godoy, I; Quintana, JC; Rodríguez, JA; Yovanovich, J, 1997) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 8.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| "The mineralocorticoid receptor antagonists (MRAs) eplerenone and spironolactone are beneficial in heart failure with reduced ejection fraction (HFrEF), but have not been prospectively compared." | 8.31 | Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study. ( Denholt, CS; Fosbøl, E; Gustafsson, F; Kristensen, SL; Køber, L; Larsson, JE; Nielsen, OW; Raja, AA; Schou, M; Thune, JJ, 2023) |
| "In the absence of previous direct comparative studies, we aimed to evaluate the effectiveness of spironolactone and eplerenone in patients with heart failure and reduced ejection fraction (HFrEF) in a real-world clinical setting." | 8.12 | Real world comparison of spironolactone and eplerenone in patients with heart failure. ( Almenar-Bonet, L; Barge-Caballero, E; Barge-Caballero, G; Bouzas-Mosquera, A; Couto-Mallón, D; Crespo-Leiro, MG; Muñiz, J; Paniagua-Martín, MJ; Pardo-Martínez, P; Prada-Delgado, Ó; Sagastagoitia-Fornie, M; Vázquez-Rodríguez, JM, 2022) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 7.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 7.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 7.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 7.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "The effect of spironolactone on clinical outcomes in patients with mild heart failure is unclear." | 7.73 | Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. ( Baliga, RR; Koelling, TM; Pitt, B; Ranganna, P, 2006) |
| "Concerns have been raised about the appropriateness of spironolactone use in some patients with heart failure." | 7.73 | Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. ( Foody, JM; Gross, CP; Havranek, EP; Krumholz, HM; Masoudi, FA; Rathore, SS; Wang, Y, 2005) |
| " In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation." | 7.72 | [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin-converting enzyme (ACE) inhibition on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 7.72 | Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Galuppo, P; Hildemann, S, 2003) |
| "We compared the rate of prescription of low-dose spironolactone among patients with heart failure in a general medical inpatient setting and in a specialist left ventricular (LV) dysfunction clinic." | 7.71 | Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. ( McMullan, R; Silke, B, 2001) |
| "Current guidelines recommend drugs which reduce neurohormonal activation as standard therapy for heart failure: angiotensin converting-enzyme (ACE) inhibitors, beta-blockers and spironolactone." | 7.71 | [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study]. ( Piérard, L, 2002) |
| "Spironolactone therapy was triggered by the detection of subclinical LVD (global longitudinal strain [GLS] ≤16%) or diastolic abnormalities (at least one of E/e' >15, E/e' >10 with left atrial enlargement [LAE] or impaired relaxation [E/A < 0." | 7.11 | Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. ( Harris, J; Marwick, TH; Potter, E; Stephenson, G; Wright, L, 2022) |
| "Eplerenone was associated with a 1." | 6.74 | The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. ( Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B, 2009) |
| "Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction." | 6.42 | Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 6.42 | Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. ( Keating, GM; Plosker, GL, 2004) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | 6.40 | [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]. ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist." | 5.91 | Role of eplerenone in the threatment of cardiovascular diseases. ( Málek, F, 2023) |
| "(1) Heart failure is diagnosed on the basis of both clinical symptoms and evaluation of cardiac function (preferably measured by echocardiography)." | 5.33 | Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. ( , 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Eplerenone is a novel selective aldosterone blocker." | 5.31 | Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002) |
| "In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity." | 5.24 | Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017) |
| "In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1month in 476 patients." | 5.24 | Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac ( Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2017) |
| "EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI) complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n = 3313)." | 5.19 | Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial. ( Adlam, D; Fay, R; Gunn, J; Iqbal, J; Parviz, Y; Pitt, B; Squire, I; Zannad, F, 2014) |
| " The investigation involved 6632 patients of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study." | 5.19 | Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s ( Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F, 2014) |
| "As myocardial fibrosis might be an important contributor to the association of obesity with left ventricular (LV) dysfunction and heart failure, we investigated the effects of spironolactone on LV function and serological fibrosis markers (procollagen type III N-terminal propeptide (PIIINP) and procollagen type I C-terminal propeptide (PICP)) in patients with obesity and abnormal LV performance." | 5.17 | Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. ( Kosmala, W; Marwick, TH; Mysiak, A; Przewlocka-Kosmala, M; Szczepanik-Osadnik, H, 2013) |
| "We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.16 | Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. ( Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F, 2012) |
| "A total of 6,496 patients from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) were categorized into 4 groups by plasma glucose concentration: ≤4." | 5.16 | Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. ( Böhm, M; Dobre, D; Kindermann, I; Lamiral, Z; Mahfoud, F; Pitt, B; Rossignol, P; Tala, S; Turgonyi, E; Ukena, C; Zannad, F, 2012) |
| "The purpose of this study was to identify the effects of spironolactone on left ventricular (LV) structure and function, and serological fibrosis markers in patients with metabolic syndrome (MS) taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.15 | A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. ( Kosmala, W; Marwick, TH; Mysiak, A; O'Moore-Sullivan, T; Przewlocka-Kosmala, M; Szczepanik-Osadnik, H, 2011) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction." | 5.14 | Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP ( Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2009) |
| " HRT from 24-hour Holter monitoring in 481 hospitalized patients after AMI with heart failure and/or diabetes with left ventricular dysfunction before randomization in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). ( Deedwania, P; Stein, PK, 2009) |
| "To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes." | 5.14 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. ( Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F, 2009) |
| "Use of selective aldosterone blockade with eplerenone within the dose range of 25 to 50 mg/d in post-acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction who are treated with standard therapy improves outcomes without an excess of risk of hyperkalemia (> or =6." | 5.13 | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "In asymptomatic patients with moderate-severe aortic stenosis, eplerenone did not slow onset of LV systolic or diastolic dysfunction, decrease LV mass, or reduce progression of valve stenosis." | 5.13 | A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. ( Cowan, BR; Doughty, RN; Edwards, C; Freidlander, D; Kerr, AJ; Occleshaw, C; Richards, AM; Stewart, RA; Whalley, GA; White, HD; Williams, M; Young, AA; Zeng, I, 2008) |
| "The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI)." | 5.12 | Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. ( Burnier, M; Erne, P; Holm, MV; Schwenkglenks, M; Szucs, TD; Weintraub, WS; Zhang, Z, 2006) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), eplerenone reduced all-cause mortality by 15% (p = 0." | 5.11 | Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. ( Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F, 2005) |
| "Spironolactone ameliorated LV diastolic dysfunction and reduced chamber stiffness in association with regression of myocardial fibrosis in mildly symptomatic patients with DCM." | 5.11 | Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. ( Amano, T; Asano, H; Ichihara, S; Iino, S; Isobe, S; Izawa, H; Kato, T; Murase, Y; Murohara, T; Nagata, K; Noda, A; Obata, K; Ohshima, S; Okumura, K; Yokota, M, 2005) |
| "A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator." | 5.11 | Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. ( Boehmer, J; Bristow, MR; Carson, P; De Marco, T; DeMets, D; DeVries, DW; DiCarlo, L; Feldman, AM; Kass, DA; Krueger, S; Saxon, LA; White, BG, 2004) |
| "Thirty medically treated ambulatory hypertensive patients (19 women, age 62+/-6 years) with exertional dyspnea, ejection fraction >50%, and diastolic dysfunction (E/A <1, E deceleration time >250 m/sec) and without ischemia were randomized to spironolactone 25 mg/d or placebo for 6 months." | 5.11 | Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. ( Cowley, D; Haluska, B; Leano, R; Marwick, TH; Mottram, PM; Stowasser, M, 2004) |
| "Eplerenone compared with placebo in the treatment of heart failure after acute myocardial infarction is effective in reducing mortality and is cost-effective in increasing years of life by commonly used criteria." | 5.11 | Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| " We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure." | 5.10 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. ( Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F, 2003) |
| "Patients hospitalized for a first episode of acute myocardial infarction were blindly and randomly assigned to receive ramipril (2." | 5.08 | [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study]. ( Castro, P; Chávez, A; Chávez, E; Corbalán, R; Godoy, I; Quintana, JC; Rodríguez, JA; Yovanovich, J, 1997) |
| "The aim of this study is to summarize the evidence on the efficacy of spironolactone (SP), eplerenone (EP), or canrenoate (CAN) in patients with left ventricular dysfunction." | 4.85 | Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. ( Ezekowitz, JA; McAlister, FA, 2009) |
| "Based on the RALES study, in patients with moderate to severe chronic heart failure and reduced left ventricular function, the nonselective aldosterone antagonist spironolactone has a well-established role in combination with ACE inhibition, beta-blockade and diuretics." | 4.83 | [Aldosterone receptor blockade after acute myocardial infarction with heart failure]. ( Bauersachs, J; Ertl, G, 2006) |
| "Either alone or in combination with other antihypertensive agents, eplerenone appears to be effective for the treatment of hypertension." | 4.82 | The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. ( Davis, KL; Nappi, JM, 2003) |
| " Recently published data with a new aldosterone blocker, eplerenone, have confirmed the benefits of aldosterone blockade in patients post-myocardial infarction, as well as in the regression of left ventricular hypertrophy in hypertensive patients and of microalbuminuria in Type 2 diabetic patients." | 4.82 | Role of the selective aldosterone receptor blockers in arterial hypertension. ( Ruilope, LM; Sierra, C, 2004) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 4.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| " Further proof of this hypothesis should be forthcoming from the results of the Eplerenone Heart Failure Efficacy and Survival Study (EPHESUS) early in 2003 in which the aldosterone receptor antagonist eplerenone is being evaluated in patients with systolic left ventricular dysfunction post myocardial infarction." | 4.81 | Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? ( Pitt, B, 2002) |
| "The mineralocorticoid receptor antagonists (MRAs) eplerenone and spironolactone are beneficial in heart failure with reduced ejection fraction (HFrEF), but have not been prospectively compared." | 4.31 | Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study. ( Denholt, CS; Fosbøl, E; Gustafsson, F; Kristensen, SL; Køber, L; Larsson, JE; Nielsen, OW; Raja, AA; Schou, M; Thune, JJ, 2023) |
| "In the absence of previous direct comparative studies, we aimed to evaluate the effectiveness of spironolactone and eplerenone in patients with heart failure and reduced ejection fraction (HFrEF) in a real-world clinical setting." | 4.12 | Real world comparison of spironolactone and eplerenone in patients with heart failure. ( Almenar-Bonet, L; Barge-Caballero, E; Barge-Caballero, G; Bouzas-Mosquera, A; Couto-Mallón, D; Crespo-Leiro, MG; Muñiz, J; Paniagua-Martín, MJ; Pardo-Martínez, P; Prada-Delgado, Ó; Sagastagoitia-Fornie, M; Vázquez-Rodríguez, JM, 2022) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Patient data were pooled from the CHARM-Preserved (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity), I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction), and TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial) studies and were examined for the association between having a pacemaker and the risk of the primary composite of cardiovascular death or HF hospitalization, the individual components of the composite, the 2 main modes of cardiovascular death (i." | 3.91 | Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. ( Anand, IS; Carson, PE; Desai, AS; Docherty, KF; Granger, CB; Jhund, PS; Komajda, M; McKelvie, RS; McMurray, JJV; Petrie, MC; Pfeffer, MA; Shen, L; Solomon, SD; Swedberg, K; Zile, MR, 2019) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 3.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 3.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 3.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 3.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| "Eplerenone suppresses inducibility of sustained atrial tachyarrhythmias, selectively prolongs atrial ERPs, and attenuates LV diastolic remodeling in RVP-induced CHF." | 3.73 | Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. ( Hoit, BD; Martovitz, NL; Ryu, K; Shroff, SC; Stambler, BS, 2006) |
| "Concerns have been raised about the appropriateness of spironolactone use in some patients with heart failure." | 3.73 | Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. ( Foody, JM; Gross, CP; Havranek, EP; Krumholz, HM; Masoudi, FA; Rathore, SS; Wang, Y, 2005) |
| "We selected three large placebo-controlled trials of patients with chronic heart failure, in which ACE-inhibitors (ACE-Is), beta-blockers, and spironolactone proved to be safe and effective." | 3.73 | Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. ( Balk, AH; Boersma, E; Cleland, JG; Follath, F; Jimenez-Navarro, M; Komajda, M; Lenzen, MJ; Reimer, WJ; Simoons, ML; Swedberg, K, 2005) |
| "The effect of spironolactone on clinical outcomes in patients with mild heart failure is unclear." | 3.73 | Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. ( Baliga, RR; Koelling, TM; Pitt, B; Ranganna, P, 2006) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin-converting enzyme (ACE) inhibition on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 3.72 | Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Galuppo, P; Hildemann, S, 2003) |
| " In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation." | 3.72 | [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003) |
| "We compared the rate of prescription of low-dose spironolactone among patients with heart failure in a general medical inpatient setting and in a specialist left ventricular (LV) dysfunction clinic." | 3.71 | Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. ( McMullan, R; Silke, B, 2001) |
| "Current guidelines recommend drugs which reduce neurohormonal activation as standard therapy for heart failure: angiotensin converting-enzyme (ACE) inhibitors, beta-blockers and spironolactone." | 3.71 | [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study]. ( Piérard, L, 2002) |
| "Spironolactone therapy was triggered by the detection of subclinical LVD (global longitudinal strain [GLS] ≤16%) or diastolic abnormalities (at least one of E/e' >15, E/e' >10 with left atrial enlargement [LAE] or impaired relaxation [E/A < 0." | 3.11 | Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. ( Harris, J; Marwick, TH; Potter, E; Stephenson, G; Wright, L, 2022) |
| "A total of 2,854 patients with STEMI with early coronary revascularization participating in the randomized EPHESUS (Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial were analyzed." | 2.82 | Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial). ( Agrinier, N; Camenzind, E; Fay, R; Girerd, N; Pitt, B; Popovic, B; Rossignol, P; Zannad, F, 2016) |
| "Eplerenone was associated with a 1." | 2.74 | The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. ( Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B, 2009) |
| "Hyperkalemia is the main potential side effect of eplerenone, especially when used in combination with other medications that can cause hyperkalemia." | 2.46 | Review article: eplerenone: an underused medication? ( Abuannadi, M; O'Keefe, JH, 2010) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 2.42 | Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. ( Keating, GM; Plosker, GL, 2004) |
| "Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction." | 2.42 | Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004) |
| "Ischemic heart failure is induced by myocardial ischemia, which is probably the commonest cause of left ventricular systolic dysfunction." | 2.42 | [Ischemic heart failure]. ( Hori, M; Inoue, K, 2003) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | 2.40 | [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]. ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| " This therapeutic association is very logical, effective and allows reduction in the dosage of the diuretic." | 2.39 | [Classic treatment of chronic heart insufficiency. What if new?]. ( Agnola, D; Aumont, MC; Juliard, JM; Karrillon, G, 1995) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist." | 1.91 | Role of eplerenone in the threatment of cardiovascular diseases. ( Málek, F, 2023) |
| "As life expectancy of patients with Duchenne muscular dystrophy (DMD) has increased to the 5th decade, in part due to improved ventilatory support, cardiomyopathy is projected to increase as a cause of death." | 1.40 | Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy. ( Evans, RA; Goldstein, RS; O'Brien, L; Varadi, R, 2014) |
| "Glucocorticoids are widely administered for the treatment of various disorders, although their long-term use results in adverse effects associated with glucocorticoid excess." | 1.39 | Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. ( Hattori, T; Iwase, E; Miyachi, M; Murase, T; Murohara, T; Nagata, K; Ohtake, M; Takahashi, K; Tsuboi, K, 2013) |
| "Myocardial infarction was induced by ligating the left anterior descending artery." | 1.35 | Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery. ( Ikeda, T; Kanemitsu, H; Komeda, M; Marui, A; Nishina, T; Tsukashita, M; Wang, J; Yoshikawa, E, 2008) |
| "Metabolic syndrome is a highly predisposing condition for cardiovascular disease and could be a cause of excess salt-induced organ damage." | 1.35 | Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T, 2008) |
| "(1) Heart failure is diagnosed on the basis of both clinical symptoms and evaluation of cardiac function (preferably measured by echocardiography)." | 1.33 | Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. ( , 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Heart failure is unique among the major cardiovascular disorders in that it alone is increasing in prevalence while there has been a striking decrease in other conditions." | 1.31 | Treatment of heart failure: state of the art and prospectives. ( Greenberg, B, 2001) |
| "Eplerenone is a novel selective aldosterone blocker." | 1.31 | Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.99) | 18.2507 |
| 2000's | 85 (56.29) | 29.6817 |
| 2010's | 52 (34.44) | 24.3611 |
| 2020's | 11 (7.28) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, J | 1 |
| Jablonowski, R | 1 |
| Mohammad, M | 1 |
| Solem, K | 1 |
| Borgquist, R | 1 |
| Ostenfeld, E | 1 |
| Arheden, H | 1 |
| Carlsson, M | 1 |
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Pardo-Martínez, P | 1 |
| Barge-Caballero, E | 1 |
| Bouzas-Mosquera, A | 1 |
| Barge-Caballero, G | 1 |
| Couto-Mallón, D | 1 |
| Paniagua-Martín, MJ | 1 |
| Sagastagoitia-Fornie, M | 1 |
| Prada-Delgado, Ó | 1 |
| Muñiz, J | 1 |
| Almenar-Bonet, L | 1 |
| Vázquez-Rodríguez, JM | 1 |
| Crespo-Leiro, MG | 1 |
| Potter, E | 1 |
| Stephenson, G | 1 |
| Harris, J | 1 |
| Wright, L | 1 |
| Marwick, TH | 4 |
| Martens, P | 1 |
| Ferreira, JP | 4 |
| Vincent, J | 6 |
| Abreu, P | 1 |
| Busselen, M | 1 |
| Mullens, W | 1 |
| Tang, WHW | 1 |
| Böhm, M | 2 |
| Pitt, B | 32 |
| Zannad, F | 17 |
| Rossignol, P | 10 |
| Málek, F | 1 |
| Larsson, JE | 1 |
| Denholt, CS | 1 |
| Thune, JJ | 1 |
| Raja, AA | 1 |
| Fosbøl, E | 1 |
| Schou, M | 1 |
| Køber, L | 1 |
| Nielsen, OW | 1 |
| Gustafsson, F | 2 |
| Kristensen, SL | 1 |
| Stienen, S | 1 |
| Cleland, JG | 6 |
| Pellicori, P | 1 |
| Girerd, N | 5 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 2 |
| Smirnov, A | 1 |
| Kalra, R | 1 |
| Gupta, K | 1 |
| Sheets, R | 1 |
| Aryal, S | 1 |
| Ebrahimi, A | 1 |
| Rajapreyar, I | 1 |
| Cribbs, MG | 1 |
| Booker, OJ | 1 |
| Prabhu, SD | 1 |
| Bajaj, NS | 1 |
| Jacobs, D | 1 |
| Moreno, V | 1 |
| Rubio, A | 1 |
| Moote, R | 1 |
| Lipscomb, J | 1 |
| Davis, H | 1 |
| Allen, S | 1 |
| Oliver, A | 1 |
| Vranic, A | 1 |
| Simovic, S | 1 |
| Ristic, P | 1 |
| Nikolic, T | 1 |
| Stojic, I | 1 |
| Srejovic, I | 1 |
| Zivkovic, V | 1 |
| Jakovljevic, V | 1 |
| Djuric, D | 1 |
| Duarte, K | 1 |
| McMurray, JJV | 4 |
| van Veldhuisen, DJ | 5 |
| Ahmad, T | 1 |
| Tromp, J | 1 |
| Rossello, X | 1 |
| Ariti, C | 1 |
| Pocock, SJ | 2 |
| Myhre, PL | 1 |
| O'Meara, E | 1 |
| Claggett, BL | 1 |
| de Denus, S | 1 |
| Jarolim, P | 1 |
| Anand, IS | 3 |
| Beldhuis, IE | 1 |
| Fleg, JL | 1 |
| Lewis, E | 1 |
| Rouleau, JL | 1 |
| Solomon, SD | 4 |
| Pfeffer, MA | 4 |
| Desai, AS | 2 |
| Shen, L | 1 |
| Jhund, PS | 1 |
| Docherty, KF | 1 |
| Petrie, MC | 1 |
| Carson, PE | 2 |
| Granger, CB | 1 |
| Komajda, M | 3 |
| McKelvie, RS | 1 |
| Swedberg, K | 5 |
| Zile, MR | 1 |
| Weir, RA | 6 |
| Petrie, CJ | 5 |
| Murphy, CA | 4 |
| Clements, S | 4 |
| Steedman, T | 6 |
| Miller, AM | 3 |
| McInnes, IB | 3 |
| Squire, IB | 3 |
| Ng, LL | 3 |
| Dargie, HJ | 6 |
| McMurray, JJ | 7 |
| Hattori, T | 2 |
| Murase, T | 2 |
| Iwase, E | 1 |
| Takahashi, K | 2 |
| Ohtake, M | 4 |
| Tsuboi, K | 1 |
| Miyachi, M | 2 |
| Murohara, T | 3 |
| Nagata, K | 3 |
| Squara, P | 1 |
| Januzzi, JL | 1 |
| Springer, J | 1 |
| Tschirner, A | 1 |
| Haghikia, A | 1 |
| von Haehling, S | 1 |
| Lal, H | 1 |
| Grzesiak, A | 1 |
| Palus, S | 1 |
| Pötsch, M | 1 |
| von Websky, K | 1 |
| Hocher, B | 1 |
| Latouche, C | 1 |
| Jaisser, F | 1 |
| Morawietz, L | 1 |
| Coats, AJ | 1 |
| Beadle, J | 1 |
| Argiles, JM | 1 |
| Thum, T | 1 |
| Földes, G | 1 |
| Doehner, W | 1 |
| Hilfiker-Kleiner, D | 1 |
| Force, T | 1 |
| Anker, SD | 1 |
| Regnault, V | 1 |
| Lagrange, J | 1 |
| Pizard, A | 2 |
| Safar, ME | 1 |
| Fay, R | 7 |
| Challande, P | 1 |
| Lacolley, P | 1 |
| Iqbal, J | 2 |
| Parviz, Y | 2 |
| Newell-Price, J | 1 |
| Al-Mohammad, A | 1 |
| Nagatomo, Y | 1 |
| Meguro, T | 1 |
| Ito, H | 1 |
| Koide, K | 1 |
| Anzai, T | 1 |
| Fukuda, K | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Adlam, D | 1 |
| Squire, I | 1 |
| Gunn, J | 1 |
| O'Brien, L | 1 |
| Varadi, R | 1 |
| Goldstein, RS | 1 |
| Evans, RA | 1 |
| Takatsu, M | 1 |
| Watanabe, S | 1 |
| Cheng, XW | 1 |
| Fiuzat, M | 1 |
| Burnett, JC | 1 |
| Bender, SB | 2 |
| DeMarco, VG | 3 |
| Padilla, J | 1 |
| Jenkins, NT | 1 |
| Habibi, J | 4 |
| Garro, M | 2 |
| Pulakat, L | 2 |
| Aroor, AR | 2 |
| Jaffe, IZ | 1 |
| Sowers, JR | 4 |
| Bostick, B | 1 |
| Jia, G | 1 |
| Domeier, TL | 1 |
| Lambert, MD | 1 |
| Nistala, R | 1 |
| Hayden, MR | 2 |
| Ma, L | 2 |
| Manrique, C | 1 |
| Mody, KP | 1 |
| Lyons, JJ | 1 |
| Jorde, UP | 1 |
| Uriel, N | 1 |
| Vizzardi, E | 1 |
| Sciatti, E | 1 |
| Bonadei, I | 1 |
| D'Aloia, A | 1 |
| Tartière-Kesri, L | 1 |
| Tartière, JM | 1 |
| Cohen-Solal, A | 2 |
| Metra, M | 1 |
| Mentz, RJ | 1 |
| Khouri, MG | 1 |
| Shah, AM | 1 |
| Claggett, B | 1 |
| Sweitzer, NK | 2 |
| Shah, SJ | 1 |
| Liu, L | 1 |
| Beygui, F | 1 |
| Cayla, G | 1 |
| Roule, V | 1 |
| Roubille, F | 1 |
| Delarche, N | 1 |
| Silvain, J | 1 |
| Van Belle, E | 1 |
| Belle, L | 1 |
| Galinier, M | 1 |
| Motreff, P | 1 |
| Cornillet, L | 1 |
| Collet, JP | 1 |
| Furber, A | 1 |
| Goldstein, P | 1 |
| Ecollan, P | 1 |
| Legallois, D | 1 |
| Lebon, A | 1 |
| Rousseau, H | 1 |
| Machecourt, J | 1 |
| Vicaut, E | 1 |
| Montalescot, G | 1 |
| Flatt, DM | 1 |
| Brown, MC | 1 |
| Mizeracki, AM | 1 |
| King, BJ | 1 |
| Weber, KT | 1 |
| Popovic, B | 1 |
| Agrinier, N | 1 |
| Camenzind, E | 1 |
| Olivier, A | 2 |
| Michel, JB | 1 |
| Ketelslegers, JM | 2 |
| Bramlage, P | 1 |
| Lamiral, Z | 3 |
| Machu, JL | 1 |
| Collier, TJ | 1 |
| Wang, H | 1 |
| Shimosawa, T | 2 |
| Matsui, H | 2 |
| Kaneko, T | 1 |
| Ogura, S | 1 |
| Uetake, Y | 1 |
| Takenaka, K | 1 |
| Yatomi, Y | 1 |
| Fujita, T | 2 |
| Mulder, P | 1 |
| Mellin, V | 1 |
| Favre, J | 1 |
| Vercauteren, M | 1 |
| Remy-Jouet, I | 1 |
| Monteil, C | 1 |
| Richard, V | 1 |
| Renet, S | 1 |
| Henry, JP | 1 |
| Jeng, AY | 1 |
| Webb, RL | 1 |
| Thuillez, C | 1 |
| Tsukashita, M | 1 |
| Marui, A | 1 |
| Nishina, T | 1 |
| Yoshikawa, E | 1 |
| Kanemitsu, H | 1 |
| Wang, J | 1 |
| Ikeda, T | 1 |
| Komeda, M | 1 |
| Ando, K | 1 |
| Kawarazaki, H | 1 |
| Nagae, A | 1 |
| Fujita, M | 1 |
| Nagase, M | 1 |
| Stewart, RA | 1 |
| Kerr, AJ | 1 |
| Cowan, BR | 1 |
| Young, AA | 1 |
| Occleshaw, C | 1 |
| Richards, AM | 1 |
| Edwards, C | 1 |
| Whalley, GA | 1 |
| Freidlander, D | 1 |
| Williams, M | 1 |
| Doughty, RN | 1 |
| Zeng, I | 1 |
| White, HD | 1 |
| Bakris, G | 1 |
| Ruilope, LM | 2 |
| DiCarlo, L | 2 |
| Mukherjee, R | 4 |
| Ezekowitz, JA | 2 |
| McAlister, FA | 2 |
| Chan, PS | 1 |
| Soto, G | 1 |
| Jones, PG | 1 |
| Nallamothu, BK | 1 |
| Zhang, Z | 3 |
| Weintraub, WS | 3 |
| Spertus, JA | 3 |
| Ramaraj, R | 2 |
| Altenberger, H | 1 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Chong, KS | 1 |
| Dalzell, JR | 1 |
| Mark, PB | 1 |
| McDonagh, TA | 1 |
| Iraqi, W | 1 |
| Angioi, M | 2 |
| Nuée, J | 1 |
| Stein, PK | 1 |
| Deedwania, P | 1 |
| Berger, R | 1 |
| Shankar, A | 1 |
| Fruhwald, F | 1 |
| Fahrleitner-Pammer, A | 1 |
| Freemantle, N | 1 |
| Tavazzi, L | 1 |
| Pacher, R | 1 |
| Shafiq, MM | 1 |
| Miller, AB | 1 |
| Gheorghiade, M | 3 |
| Khan, S | 1 |
| Blair, JE | 1 |
| Harinstein, ME | 1 |
| Krum, H | 3 |
| Adamopoulos, C | 1 |
| Ahmed, A | 1 |
| Filippatos, G | 1 |
| Susic, D | 2 |
| Varagic, J | 2 |
| Frohlich, ED | 2 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Udelson, JE | 1 |
| Feldman, AM | 2 |
| Greenberg, B | 2 |
| Solomon, HA | 1 |
| Konstam, MA | 1 |
| Martin, TN | 1 |
| Balmain, S | 1 |
| Wagner, GS | 1 |
| Ozaydin, M | 1 |
| Varol, E | 1 |
| Türker, Y | 1 |
| Peker, O | 1 |
| Erdoğan, D | 1 |
| Doğan, A | 1 |
| Ibrişim, E | 1 |
| Ito, K | 1 |
| Hirooka, Y | 1 |
| Sunagawa, K | 1 |
| Dabrowski, R | 1 |
| Pedzich-Placha, E | 1 |
| Abuannadi, M | 1 |
| O'Keefe, JH | 2 |
| Rainey, WE | 1 |
| Whaley-Connell, AT | 1 |
| Tsorlalis, IK | 1 |
| Fraser, R | 1 |
| Connell, JM | 1 |
| Bhandari, S | 1 |
| Tala, S | 2 |
| Dobre, D | 2 |
| Leung, DY | 1 |
| Kosmala, W | 2 |
| Przewlocka-Kosmala, M | 2 |
| Szczepanik-Osadnik, H | 2 |
| Mysiak, A | 2 |
| O'Moore-Sullivan, T | 1 |
| Butler, J | 1 |
| Collins, SP | 1 |
| Givertz, MM | 1 |
| Teerlink, JR | 2 |
| Walsh, MN | 1 |
| Albert, NM | 1 |
| Westlake Canary, CA | 1 |
| Colvin-Adams, M | 1 |
| Fang, JC | 1 |
| Hernandez, AF | 1 |
| Hershberger, RE | 1 |
| Katz, SD | 1 |
| Rogers, JG | 1 |
| Stevenson, WG | 1 |
| Tang, WH | 1 |
| Stough, WG | 1 |
| Starling, RC | 1 |
| Ukena, C | 1 |
| Mahfoud, F | 1 |
| Kindermann, I | 1 |
| Turgonyi, E | 1 |
| Cowie, MR | 1 |
| Kamyshnikova, LA | 1 |
| Efremova, OA | 1 |
| Krämer, B | 1 |
| Porcu, M | 1 |
| Hausmann, MJ | 1 |
| Liel-Cohen, N | 1 |
| Suzuki, G | 1 |
| Morita, H | 1 |
| Mishima, T | 1 |
| Sharov, VG | 1 |
| Todor, A | 1 |
| Tanhehco, EJ | 1 |
| Rudolph, AE | 2 |
| McMahon, EG | 2 |
| Goldstein, S | 1 |
| Sabbah, HN | 1 |
| Jessup, M | 1 |
| Remme, W | 1 |
| Neaton, J | 1 |
| Martinez, F | 2 |
| Roniker, B | 1 |
| Bittman, R | 1 |
| Hurley, S | 1 |
| Kleiman, J | 1 |
| Gatlin, M | 1 |
| Inoue, K | 1 |
| Hori, M | 1 |
| Qin, W | 1 |
| Bond, BR | 1 |
| Rocha, R | 1 |
| Blomme, EA | 1 |
| Goellner, JJ | 1 |
| Funder, JW | 1 |
| Coletta, AP | 1 |
| Nikitin, N | 1 |
| Louis, A | 1 |
| Clark, A | 1 |
| Massie, BM | 1 |
| Aggarwal, A | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Blaustein, DA | 1 |
| Schwenk, MH | 1 |
| Masoudi, FA | 2 |
| Havranek, EP | 2 |
| Wolfe, P | 1 |
| Gross, CP | 2 |
| Rathore, SS | 2 |
| Steiner, JF | 1 |
| Ordin, DL | 1 |
| Krumholz, HM | 2 |
| McKee, SP | 1 |
| Leslie, SJ | 1 |
| LeMaitre, JP | 1 |
| Webb, DJ | 1 |
| Denvir, MA | 1 |
| Doggrell, S | 1 |
| Taylor, AL | 1 |
| Fraccarollo, D | 1 |
| Galuppo, P | 1 |
| Hildemann, S | 1 |
| Christ, M | 1 |
| Ertl, G | 2 |
| Bauersachs, J | 2 |
| Stier, CT | 1 |
| Rajagopalan, S | 1 |
| Davis, KL | 1 |
| Nappi, JM | 1 |
| Kolloch, R | 1 |
| Offers, E | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Ohnishi, M | 1 |
| Tsutsui, T | 1 |
| Ishii, C | 1 |
| Ohno, K | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Yamamoto, T | 1 |
| Takayama, T | 1 |
| Dohke, T | 1 |
| Horie, M | 1 |
| Sierra, C | 1 |
| Bristow, MR | 1 |
| Saxon, LA | 1 |
| Boehmer, J | 1 |
| Krueger, S | 1 |
| Kass, DA | 1 |
| De Marco, T | 1 |
| Carson, P | 1 |
| DeMets, D | 1 |
| White, BG | 1 |
| DeVries, DW | 1 |
| Mottram, PM | 1 |
| Haluska, B | 1 |
| Leano, R | 1 |
| Cowley, D | 1 |
| Stowasser, M | 1 |
| Yoshiyama, M | 1 |
| Omura, T | 1 |
| Yoshikawa, J | 1 |
| Kochsiek, K | 1 |
| Wahed, MI | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Yamaguchi, K | 1 |
| Takahashi, T | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Keating, GM | 1 |
| Plosker, GL | 1 |
| Dzau, VJ | 1 |
| Conti, CR | 1 |
| Mahoney, EM | 1 |
| Kolm, P | 1 |
| Caro, J | 1 |
| Ishak, J | 1 |
| Goldberg, R | 1 |
| Tooley, J | 1 |
| Willke, R | 1 |
| Sueta, CA | 1 |
| Bertoni, AG | 1 |
| Massing, MW | 1 |
| McArdle, J | 1 |
| Duren-Winfield, V | 1 |
| Davis, J | 1 |
| Croft, JB | 1 |
| Goff, DC | 1 |
| Veliotes, DG | 1 |
| Woodiwiss, AJ | 1 |
| Deftereos, DA | 1 |
| Gray, D | 1 |
| Osadchii, O | 1 |
| Norton, GR | 1 |
| Wang, Y | 1 |
| Foody, JM | 1 |
| White, H | 1 |
| Nicolau, J | 1 |
| Aschermann, M | 1 |
| Stecker, EC | 1 |
| McAnulty, JH | 1 |
| Houpe, D | 1 |
| Peltier, M | 1 |
| Béguin, M | 1 |
| Lévy, F | 1 |
| Slama, M | 1 |
| Chapelain, K | 1 |
| Tribouilloy, C | 1 |
| Tu, JV | 1 |
| Newman, A | 1 |
| Lee, DS | 1 |
| Kimber, S | 1 |
| Cujec, B | 1 |
| Armstrong, PW | 2 |
| Lenzen, MJ | 2 |
| Boersma, E | 1 |
| Reimer, WJ | 1 |
| Balk, AH | 1 |
| Follath, F | 2 |
| Jimenez-Navarro, M | 1 |
| Simoons, ML | 1 |
| Izawa, H | 1 |
| Isobe, S | 1 |
| Asano, H | 1 |
| Amano, T | 1 |
| Ichihara, S | 1 |
| Kato, T | 1 |
| Ohshima, S | 1 |
| Murase, Y | 1 |
| Iino, S | 1 |
| Obata, K | 1 |
| Noda, A | 1 |
| Okumura, K | 1 |
| Yokota, M | 1 |
| Landmesser, U | 1 |
| Drexler, H | 1 |
| Baliga, RR | 1 |
| Ranganna, P | 1 |
| Koelling, TM | 1 |
| Shroff, SC | 1 |
| Ryu, K | 1 |
| Martovitz, NL | 1 |
| Hoit, BD | 1 |
| Stambler, BS | 1 |
| Ram, R | 1 |
| Van Wagoner, DR | 1 |
| Szucs, TD | 1 |
| Holm, MV | 1 |
| Schwenkglenks, M | 1 |
| Burnier, M | 1 |
| Erne, P | 1 |
| Ahn, J | 1 |
| Matavelli, L | 1 |
| Lainscak, M | 1 |
| Ferrari, R | 1 |
| McMurray, J | 1 |
| Lopez-Sendon, J | 1 |
| Abuissa, H | 1 |
| Stas, S | 1 |
| Whaley-Connell, A | 1 |
| Appesh, L | 1 |
| Karuparthi, PR | 1 |
| Qazi, M | 1 |
| Morris, EM | 1 |
| Cooper, SA | 1 |
| Link, CD | 1 |
| Stump, C | 1 |
| Hay, M | 1 |
| Ferrario, C | 1 |
| Ennezat, PV | 1 |
| Gonin, X | 1 |
| Darchis, J | 1 |
| De Groote, P | 1 |
| Lamblin, N | 1 |
| Bauters, C | 1 |
| Lejemtel, T | 1 |
| Asseman, P | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Chizyński, K | 1 |
| Goch, JH | 1 |
| Verma, A | 1 |
| Aumont, MC | 1 |
| Agnola, D | 1 |
| Juliard, JM | 1 |
| Karrillon, G | 1 |
| Brilla, CG | 1 |
| Schencking, M | 1 |
| Scheer, C | 1 |
| Rupp, H | 1 |
| Rodríguez, JA | 1 |
| Godoy, I | 1 |
| Castro, P | 1 |
| Quintana, JC | 1 |
| Chávez, E | 1 |
| Yovanovich, J | 1 |
| Corbalán, R | 1 |
| Chávez, A | 1 |
| López Herrero, F | 1 |
| Pardo Alvarez, J | 1 |
| McMullan, R | 1 |
| Silke, B | 1 |
| Piérard, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure[NCT00232180] | Phase 3 | 2,743 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study[NCT00132093] | Phase 4 | 100 participants | Interventional | 2005-04-30 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL[NCT01059136] | Phase 3 | 1,603 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Baseline Characteristics, Processes of Care, System-related Factors, and Clinical Outcomes Associated With the Quality and Safety of Initial Management for ST-segment Elevation Myocardial Infarction: A Multicenter Cohort Study[NCT02788344] | 6,920 participants (Actual) | Observational | 2017-05-15 | Completed | |||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure[NCT00082589] | Phase 4 | 250 participants | Interventional | 2004-04-30 | Completed | ||
| MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)[NCT01882179] | Phase 3 | 61 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA Study.[NCT00725738] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2008-05-31 | Recruiting | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Eplerenone for Central Serous Chorioretinopathy: A Pilot Study[NCT01822561] | Phase 2 | 17 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy[NCT01996397] | 34 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)[NCT02026102] | 15 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| A Randomized and Double-blind Study to Evaluate the Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects[NCT01813201] | Phase 4 | 14 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure[NCT00180258] | Phase 2/Phase 3 | 2,200 participants | Interventional | 2000-01-31 | Completed | ||
| Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System[NCT00433043] | Phase 4 | 2 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Insufficient enrollment) | ||
| CRT-P or CRT-D in Patients With Dilated Cardiomyopathy and Heart Failure Without LGE-CMR High-risk Markers[NCT04139460] | 924 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| High Intensity His Bundle Pacing in Heart Failure Patients With Narrow QRS Outcome Study[NCT05491655] | 34 participants (Anticipated) | Interventional | 2023-03-29 | Recruiting | |||
| The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response[NCT02541773] | 58 participants (Anticipated) | Observational | 2013-11-30 | Active, not recruiting | |||
| Pacemaker Induced Transient Dyssynchrony for Treating Heart Failure (PITA-HF): Feasibility, Safety, and Tolerability[NCT04159454] | 8 participants (Actual) | Interventional | 2020-11-20 | Completed | |||
| ElectroCRT - Left Ventricular Lead Implant and Optimization Guided by Electrocardiography in Cardiac Resynchronization Therapy[NCT02346097] | 122 participants (Actual) | Interventional | 2015-02-16 | Completed | |||
| Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy[NCT03356652] | 93 participants (Anticipated) | Interventional | 2018-03-08 | Recruiting | |||
| Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.[NCT01545180] | 665 participants (Actual) | Observational | 2012-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 288 |
| Placebo: Double-blind Phase | 392 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 249 |
| Placebo: Double-blind Phase | 356 |
Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 408 | 463 |
| Placebo: Double-blind Phase | 491 | 552 |
Death due to any cause. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 171 | 205 |
| Placebo: Double-blind Phase | 213 | 253 |
Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 462 | 530 |
| Placebo: Double-blind Phase | 569 | 636 |
Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 270 | 311 |
| Placebo: Double-blind Phase | 376 | 418 |
First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 304 | 346 |
| Placebo: Double-blind Phase | 399 | 439 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 147 | 178 |
| Placebo: Double-blind Phase | 185 | 215 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 45 | 49 |
| Placebo: Double-blind Phase | 33 | 40 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 21 | 24 |
| Placebo: Double-blind Phase | 26 | 31 |
First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 164 | 186 |
| Placebo: Double-blind Phase | 253 | 277 |
Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 170 | 194 |
| Placebo: Double-blind Phase | 262 | 287 |
First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 4 | 4 |
| Placebo: Double-blind Phase | 3 | 3 |
First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 9 | 10 |
| Placebo: Double-blind Phase | 8 | 10 |
First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 61 | 76 |
| Placebo: Double-blind Phase | 59 | 78 |
First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 33 | 45 |
| Placebo: Double-blind Phase | 41 | 53 |
New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 950, 937) | Up to 59.5 months (complete DB) (n= 956, 940) | |
| Eplerenone: Double-blind Phase | 32 | 41 |
| Placebo: Double-blind Phase | 52 | 59 |
The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 904, 973) | Up to 59.5 months (complete DB) (n= 907, 975) | |
| Eplerenone: Double-blind Phase | 34 | 42 |
| Placebo: Double-blind Phase | 40 | 47 |
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | logMAR (Mean) |
|---|---|
| Patients That Took Eplerenone | -0.03 |
Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | Microns (Mean) |
|---|---|
| Patients That Received Eplerenone | -26 |
Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | mEq/L (Mean) |
|---|---|
| Patients That Received Eplerenone | 0.11 |
Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | microns (Mean) |
|---|---|
| Patients That Received Eplerenone | 29.8 |
Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | participants (Number) |
|---|---|
| Patients That Took Eplerenone | 0 |
25 reviews available for spironolactone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Topics: Death, Sudden, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Co | 2019 |
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolact | 2014 |
Heart failure: the role for mineralocorticoid receptor antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolact | 2014 |
Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonist | 2016 |
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
Topics: Aged; Cause of Death; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocor | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; | 2009 |
Review article: eplerenone: an underused medication?
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Hypertrophy, | 2010 |
Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Topics: Diuretics; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spiron | 2002 |
[Ischemic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Fib | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplere | 2003 |
Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Contro | 2003 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal | 2003 |
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
Topics: Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Miner | 2003 |
The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
Topics: Area Under Curve; Clinical Trials as Topic; Drug Interactions; Eplerenone; Humans; Hyperkalemia; Hyp | 2003 |
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Digoxin; Enzyme Inhibitors; Eplerenone; Female; Human | 2004 |
Role of the selective aldosterone receptor blockers in arterial hypertension.
Topics: Animals; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2004 |
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineraloc | 2004 |
Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Topics: Animals; Area Under Curve; Economics, Pharmaceutical; Eplerenone; Half-Life; Heart Failure; Humans; | 2004 |
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2004 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failur | 2005 |
[Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diu | 2006 |
Aldosterone blockade in post-acute myocardial infarction heart failure.
Topics: Algorithms; Cardiac Output, Low; Eplerenone; Humans; Hyperkalemia; Hypotension; Mineralocorticoid Re | 2006 |
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Topics: Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor | 2007 |
[Classic treatment of chronic heart insufficiency. What if new?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digitalis Glycosides; Diuretics; Drug The | 1995 |
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Topics: Animals; Diuretics; Endomyocardial Fibrosis; Heart Failure; Humans; Microcirculation; Mineralocortic | 1997 |
39 trials available for spironolactone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; | 2022 |
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Topics: Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pro | 2022 |
Galectin-3 and cardiac function in survivors of acute myocardial infarction.
Topics: Aged; Eplerenone; Extracellular Matrix; Female; Galectin 3; Humans; Magnetic Resonance Imaging; Male | 2013 |
Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s
Topics: Aged; Arterial Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorti | 2014 |
Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
Topics: Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Eplerenone; Female; Humans; Male; Middle | 2014 |
Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.
Topics: Aged; Echocardiography; Female; Follow-Up Studies; Heart Failure, Systolic; Heart Ventricles; Humans | 2015 |
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart | 2015 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial).
Topics: Aged; Cause of Death; Double-Blind Method; Electrocardiography; Eplerenone; Female; Follow-Up Studie | 2016 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; | 2017 |
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Topics: Aged; Aldosterone; Drug Monitoring; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Middl | 2017 |
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Blood Flow Velocity; Echocardiography, Doppler; Eplerenone; Female; Hum | 2008 |
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Logistic Models; Male; Min | 2008 |
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Topics: Acute Disease; Aged; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Healt | 2009 |
Plasma apelin concentration is depressed following acute myocardial infarction in man.
Topics: Apelin; Biomarkers; Chromatography, High Pressure Liquid; Double-Blind Method; Echocardiography; Epl | 2009 |
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP
Topics: Aged; Biomarkers; Collagen Type I; Collagen Type III; Death, Sudden, Cardiac; Eplerenone; Extracellu | 2009 |
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study).
Topics: Aged; Electrocardiography, Ambulatory; Eplerenone; Female; Heart Failure; Heart Rate; Humans; Male; | 2009 |
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; B | 2009 |
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Length of Sta | 2009 |
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Topics: Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Hum | 2009 |
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Topics: Aged; Cohort Studies; Double-Blind Method; Eplerenone; Female; Gated Blood-Pool Imaging; Heart Failu | 2010 |
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction.
Topics: Chi-Square Distribution; Contrast Media; Double-Blind Method; Eplerenone; Female; Gadolinium DTPA; H | 2010 |
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Fem | 2011 |
Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Topics: Aged; Eplerenone; Glomerular Filtration Rate; Heart Failure; Heart Failure, Systolic; Humans; Kidney | 2012 |
A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2011 |
Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS.
Topics: Aged; Blood Glucose; Diabetes Complications; Double-Blind Method; Eplerenone; Female; Humans; Hyperg | 2012 |
Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Interleukins; Male; Matrix Metall | 2012 |
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Topics: Body Mass Index; Double-Blind Method; Echocardiography, Doppler; Female; Fibrosis; Follow-Up Studies | 2013 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplere | 2003 |
Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
Topics: Aged; Defibrillators, Implantable; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Min | 2003 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Topics: Aged; Aorta; Compliance; Diastole; Dyspnea; Exercise Test; Exercise Tolerance; Female; Heart Atria; | 2004 |
[Angiotensin receptor blockers in heart failure. CHARM Study].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Topics: Aged; Cause of Death; Comorbidity; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Eplerenon | 2005 |
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Topics: Aged; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 2005 |
Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
Topics: Adult; Aged; Biopsy; Cardiomyopathy, Dilated; Female; Fibrosis; Heart Failure; Humans; Male; Middle | 2005 |
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
Topics: Adult; Aged; Cost-Benefit Analysis; Eplerenone; Female; Health Care Costs; Humans; Male; Middle Aged | 2006 |
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Disease-Free Survival; Double-Blind | 1997 |
88 other studies available for spironolactone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction.
Topics: Aged; Aspirin; Body Mass Index; Cicatrix; Diuretics; Female; Fibrosis; Follow-Up Studies; Heart Fail | 2021 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Real world comparison of spironolactone and eplerenone in patients with heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spir | 2022 |
Role of eplerenone in the threatment of cardiovascular diseases.
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2023 |
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
Topics: Aged; Cohort Studies; Eplerenone; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Treatm | 2023 |
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
Topics: Collagen Type I; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardi | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Death, Sudden, Cardiac; Diastole; Echocardiography; Female; Heart Arrest; Heart Failure; Human | 2020 |
Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems.
Topics: Eplerenone; Heart Failure; Hospitals; Humans; Mineralocorticoid Receptor Antagonists; Patient Discha | 2023 |
The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats.
Topics: Animals; Coronary Circulation; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; He | 2017 |
Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Hyperkalemia; Male; | 2018 |
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; | 2018 |
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2019 |
Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Topics: Animals; Atrophy; Blood Pressure; Corticosterone; Disease Models, Animal; Fibrosis; Heart Diseases; | 2013 |
Systematic approach: an evidence management strategy for better decision-making.
Topics: Decision Making; Eplerenone; Evidence-Based Medicine; Humans; Mineralocorticoid Receptor Antagonists | 2013 |
Letter by Januzzi regarding article, "galectin-3 and cardiac function in survivors of acute myocardial infarction".
Topics: Female; Galectin 3; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spi | 2013 |
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolo | 2014 |
Response to Letter Regarding Article, “Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction”.
Topics: Female; Galectin 3; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spi | 2013 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 2014 |
Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Eplerenone; Male; Mice; Mice, K | 2014 |
Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diur | 2014 |
Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized Dahl salt-sensitive rats.
Topics: Adrenalectomy; Animals; Blood Pressure; Collagen Type I; Collagen Type III; Corticosterone; Disease | 2014 |
Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling.
Topics: Acute Kidney Injury; Animals; Galectin 3; Heart Failure; Interleukins; Male; Myocardial Infarction; | 2015 |
Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.
Topics: Animals; Diastole; Disease Models, Animal; Echocardiography; Heart Ventricles; Mineralocorticoid Rec | 2015 |
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.
Topics: Animals; Cardiomegaly; Diastole; Diet, High-Fat; Diet, Western; Dietary Sucrose; Disease Models, Ani | 2015 |
A cold taken to heart.
Topics: Adenoviridae Infections; Adult; Biopsy; Cardiovascular Agents; Combined Modality Therapy; Defibrilla | 2015 |
Longitudinal Strain in Heart Failure With Preserved Ejection Fraction: Is There a Role for Prognostication?
Topics: Female; Heart Failure, Systolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolacton | 2015 |
MRAs in Patients With AMI Without Early Evidence of Heart Failure: Time for Reappraisal?
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2016 |
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Topics: Angiotensin II; Animals; Antioxidants; Cyclic N-Oxides; Diastole; Disease Models, Animal; Eplerenone | 2008 |
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
Topics: Angiotensin Receptor Antagonists; Animals; Cytochrome P-450 CYP11B2; Endothelium, Vascular; Fadrozol | 2008 |
Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.
Topics: Animals; Heart Aneurysm; Heart Ventricles; Hemodynamics; Lung; Male; Mineralocorticoid Receptor Anta | 2008 |
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Dopple | 2008 |
Spironolactone alleviates late cardiac remodeling after left ventricular restoration.
Topics: Humans; Spironolactone; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
Topics: Aortic Valve Stenosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Spiron | 2009 |
Isolated left ventricular hypertrabeculation/noncompaction in a Turner mosaic with male phenotype.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, | 2009 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Association between renin-angiotensin-aldosterone system blockers and postoperative atrial fibrillation in patients with mild and moderate left ventricular dysfunction.
Topics: Adrenergic Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensi | 2010 |
Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload.
Topics: Animals; Brain; Epithelial Sodium Channels; Eplerenone; Hypertension; Male; Mice; Mice, Inbred ICR; | 2010 |
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 2010 |
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression.
Topics: Animals; Blood Pressure; Cardiomegaly; Endomyocardial Fibrosis; Male; Mineralocorticoid Receptor Ant | 2011 |
Aldosterone blockade in metabolic syndrome: hitting the target or still missing some links?
Topics: Female; Humans; Hypertrophy, Left Ventricular; Male; Metabolic Syndrome; Mineralocorticoid Receptor | 2011 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho | 2012 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans | 2012 |
[Structural and functional changes in myocardium of patients with chronic heart failure treated with spironolactone].
Topics: Adult; Chronic Disease; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; | 2012 |
[Is eplerenone nephrotoxic?].
Topics: Aged; Controlled Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Eplerenone; | 2012 |
The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Hea | 2002 |
Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function.
Topics: Aged; Humans; Male; Mineralocorticoid Receptor Antagonists; Peritoneal Dialysis; Spironolactone; Ven | 2002 |
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Administration, Oral; Animals; Chronic Disease; Disease Models, Animal; Disease Progression; Dogs; E | 2002 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Research Design; | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Death, Sudden, Cardiac; Eplerenone; Humans; Hypokalemia; Mineralocorticoid Receptor Antagonists; Myo | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Contraindications; Creatinine; Eplerenone; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagoni | 2003 |
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2003 |
Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians.
Topics: Aged; Cardiology; Chronic Disease; Digoxin; Diuretics; Female; Guideline Adherence; Heart Failure; H | 2003 |
The African-American Heart Failure Trial (A-HeFT): rationale and methodology.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Western; Drug Synergism; Drug Therapy, | 2003 |
[Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
Topics: Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Diuretics; Double-Blind Method; Epleren | 2003 |
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid | 2003 |
Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Case-Control Studies | 2004 |
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Topics: Animals; Autoimmune Diseases; Cardiomyopathy, Dilated; Collagen Type III; Dose-Response Relationship | 2005 |
Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2005 |
Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medication utilization.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Comorbidity; Diuretics; | 2005 |
Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.
Topics: Adrenergic beta-Agonists; Animals; Collagen; Echocardiography; Heart; Hypertension; Hypertrophy, Lef | 2005 |
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
Topics: Aged; Aged, 80 and over; Cohort Studies; Creatinine; Diuretics; Drug Prescriptions; Female; Follow-U | 2005 |
[Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
[Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
Letter regarding article by Weintraub et al, "Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure".
Topics: Cost-Benefit Analysis; Drug Costs; Eplerenone; Health Care Costs; Humans; Myocardial Infarction; Pla | 2005 |
Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Foll | 2005 |
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting | 2006 |
Sudden death in patients with myocardial infarction.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; M | 2005 |
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2005 |
Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial | 2006 |
Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; H | 2006 |
Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR.
Topics: Animals; Blood Pressure; Coronary Circulation; Eplerenone; Fibrosis; Hypertension; Male; Mineralocor | 2007 |
International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Diur | 2007 |
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Eplerenone; Female; Heart Failure; Humans; H | 2008 |
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Topics: Animals; Animals, Genetically Modified; Blood Pressure; Cardiomegaly; Chronic Disease; Fibrosis; Mag | 2007 |
Delayed recovery of left ventricular systolic dysfunction: ''give time to medical therapy''.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Diuretics; Drug T | 2007 |
[Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adult; Aged; Cause of Death; Comorbidity; Female; Follow-Up Studies; Heart Failure; H | 2006 |
[Spironolactone in heart failure].
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Primary Health Care; Rando | 2000 |
Left ventricular dysfunction: causes, natural history, and hopes for reversal.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Coronary Disease; | 2000 |
Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic.
Topics: Diuretics; Heart Failure; Humans; Medicine; Northern Ireland; Practice Patterns, Physicians'; Specia | 2001 |
Treatment of heart failure: state of the art and prospectives.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; | 2001 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |